Antibody Information

General Information of This Antibody

Antibody ID	ANI0DMOQQ
Antibody Name	hz1613F12
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1
Antigen Name	Tyrosine-protein kinase receptor UFO (AXL)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

hz1613F12-E-13 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Positive AXL expression (AXL+++/++)
Method Description	Briefly, cells were seeded into 96 well multi-well plates the day before drug treatment at 2500 cells per well. ADCs and controls were serially diluted and then added to the mw-96 plates. Cells were then incubated for 6 days at 37°C and 5% CO₂.
In Vitro Model	Renal cell carcinoma	SN12C cells		CVCL_1705
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10.00 nM	Negative AXL expression (AXL-)
Method Description	Briefly, cells were seeded into 96 well multi-well plates the day before drug treatment at 2500 cells per well. ADCs and controls were serially diluted and then added to the mw-96 plates. Cells were then incubated for 6 days at 37°C and 5% CO₂.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

hz1613F12-G-13 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Positive AXL expression (AXL+++/++)
Method Description	Briefly, cells were seeded into 96 well multi-well plates the day before drug treatment at 2500 cells per well. ADCs and controls were serially diluted and then added to the mw-96 plates. Cells were then incubated for 6 days at 37°C and 5% CO₂.
In Vitro Model	Renal cell carcinoma	SN12C cells		CVCL_1705
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10.00 nM	Negative AXL expression (AXL-)
Method Description	Briefly, cells were seeded into 96 well multi-well plates the day before drug treatment at 2500 cells per well. ADCs and controls were serially diluted and then added to the mw-96 plates. Cells were then incubated for 6 days at 37°C and 5% CO₂.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

References

Ref 1	Antibody-drug-conjugate and its use for the treatment of cancer.